- Home
- VLGEA vs HUMA Comparison
VLGEA vs HUMA Comparison
Compare VLGEA & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLGEA
- HUMA
- Stock Information
- Founded
- VLGEA 1937
- HUMA 2004
- Country
- VLGEA United States
- HUMA United States
- Employees
- VLGEA N/A
- HUMA N/A
- Industry
- VLGEA Food Chains
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- VLGEA Consumer Staples
- HUMA Health Care
- Exchange
- VLGEA Nasdaq
- HUMA Nasdaq
- Market Cap
- VLGEA 501.1M
- HUMA 503.1M
- IPO Year
- VLGEA N/A
- HUMA N/A
- Fundamental
- Price
- VLGEA $31.79
- HUMA $3.54
- Analyst Decision
- VLGEA
- HUMA Strong Buy
- Analyst Count
- VLGEA 0
- HUMA 7
- Target Price
- VLGEA N/A
- HUMA $13.43
- AVG Volume (30 Days)
- VLGEA 19.8K
- HUMA 1.5M
- Earning Date
- VLGEA 03-04-2025
- HUMA 03-21-2025
- Dividend Yield
- VLGEA 3.13%
- HUMA N/A
- EPS Growth
- VLGEA 2.47
- HUMA N/A
- EPS
- VLGEA 3.48
- HUMA N/A
- Revenue
- VLGEA $2,257,909,000.00
- HUMA N/A
- Revenue This Year
- VLGEA N/A
- HUMA N/A
- Revenue Next Year
- VLGEA N/A
- HUMA $4,344.68
- P/E Ratio
- VLGEA $9.26
- HUMA N/A
- Revenue Growth
- VLGEA 3.42
- HUMA N/A
- 52 Week Low
- VLGEA $24.57
- HUMA $2.81
- 52 Week High
- VLGEA $35.34
- HUMA $9.97
- Technical
- Relative Strength Index (RSI)
- VLGEA 37.06
- HUMA 29.77
- Support Level
- VLGEA $33.90
- HUMA $3.70
- Resistance Level
- VLGEA $34.83
- HUMA $4.14
- Average True Range (ATR)
- VLGEA 0.76
- HUMA 0.22
- MACD
- VLGEA -0.35
- HUMA -0.06
- Stochastic Oscillator
- VLGEA 10.35
- HUMA 0.00
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.